/ /

  • linkedin
  • Increase Font
  • Sharebar

    Drug delivery systems could improve poor adherence



    The Envisia ENV515 is a depot delivery of travoprost based on a new technology for nano- and microparticle formation. It relies on a proprietary injector and needle, similar to the ones for Bimatoprost SR.

    In a phase IIa study, 5 subjects experienced similar reductions in IOP to those seen with timolol when treated after a washout period.

    "The really impressive thing to me was not that these drugs worked, but that in this case, the single injection in these patients lasted 11 months," said Dr. Myers. "That's pretty close to once-a-year dosing. For a patient, that's a pretty good tradeoff for those who can be controlled with just one medication."

    As with Bimatoprost SR, side effects related to injection procedure and were not severe, he said. The hyperemia scores were equivalent to those seen with a topical prostaglandin.

    "With topical medication, you have to use much more because you're applying to the outside of the eye," said Dr. Myers. "So we hope with depot drugs, another benefit will be fewer side effects."


    New Call-to-action


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results